|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UNDER CONSTRUCTION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Saturday, October 14, 2006
TeGenero Omitted Important Data in London Drug Trial
TeGenero AG, the developer of an experimental drug that left six men with organ failure, didn't supply information that could have alerted U.K. regulators to the risks..... In the trial in March, the men were given a laboratory- produced antibody designed to treat arthritis, leukemia and multiple sclerosis at a north London facility run by Waltham, Massachusetts-based Parexel International Corp. The men were hospitalized for weeks after severe reactions to injections of the medicine developed by TeGenero..... |